The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

AstraZeneca’s dazzling data & a new VC bio-fund

By Damian Garde and Meghana Keshavan

The READOUT
The Readout

A novel treatment idea in Covid-19 & Denali’s big test

By Damian Garde

The READOUT
The Readout

Moderna’s $89M in insider sales & Sanofi’s billions in dry powder

By Damian Garde

The READOUT
The Readout

Merck enters the Covid-19 vaccine fray & a positive readout from Argenx

By Meghana Keshavan

The READOUT
The Readout

Downgrading Covid-19 severity & a GVHD win

By Meghana Keshavan

The READOUT
The Readout

The raucous backstory behind a Covid-19 vaccine & a make-or-break IPO

By Damian Garde

The READOUT
The Readout

Experts prod Moderna’s coronavirus claims & biotech moves the markets

By Damian Garde

The READOUT
The Readout

A little Moderna data goes a long way & Gilead calms Wall Street

By Damian Garde

The READOUT
The Readout

The WHO patent pool & Pfizer’s Duchenne progress

By Meghana Keshavan

The READOUT
The Readout

BIO’s new CEO & naming a price for remdesivir

By Meghana Keshavan

The READOUT
The Readout

Celgene’s deteriorating legacy & Allogene’s early promise

By Damian Garde

The READOUT
The Readout

Alexion’s activist problem & CRISPR’ing sickle cell

By Damian Garde

The READOUT
The Readout

Moderna’s valuation & a potential ‘game changer’ in heart disease

By Damian Garde

The READOUT
The Readout

Inside the NIH remdesivir study & Maryland’s price gouging veto

By Meghana Keshavan

The READOUT
The Readout

Moderna vaccine moves to Phase 2 & how four biotechs will fare during Covid-19

By Meghana Keshavan

The READOUT
The Readout

A (preliminary) win for the microbiome & a down-to-the-wire biotech payday

By Damian Garde

The READOUT
The Readout

A reality check on Covid-19 vaccines & a CEO’s lucrative ‘sacrifice’

By Damian Garde

The READOUT
The Readout

World to Gilead: Don’t mess this up. Plus: Insider sales of a hyped-up stock

By Damian Garde

The READOUT
The Readout

On Covid-19 price gouging & why Theranos might have thrived in pandemic

By Meghana Keshavan

The READOUT
The Readout

Remdesivir supply chains & floundering startups

By Meghana Keshavan

The READOUT
The Readout

Gilead’s Covid-19 drug works & Vertex has an instant blockbuster

By Damian Garde

The READOUT
The Readout

Hope for ready-made CAR-T & a threat to Biogen

By Damian Garde

The READOUT
The Readout

How to interpret remdesivir data & biopharma’s big earnings week

By Damian Garde

The READOUT
The Readout

AACR begins & the dawn of a ‘biotech century’

By Meghana Keshavan

The READOUT
The Readout

More remdesivir data & Eli Lilly’s profit boost

By Meghana Keshavan

The READOUT
The Readout

More delays from Biogen & shrinking startup valuation

By Meghana Keshavan

The READOUT
The Readout

BARDA’s chief is out & FDA green-lights ADHD game

By Meghana Keshavan

The READOUT
The Readout

What’s up at Biogen, an image boost for pharma, & Francis Collins on Covid-19

By Meghana Keshavan

The READOUT
The Readout

Novartis starts a hydroxychloroquine trial, a new breast cancer drug approved, & a new poll

By Meghana Keshavan

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy